• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物计量马尔可夫模型教程。

A tutorial on pharmacometric Markov models.

作者信息

Ooi Qing Xi, Plan Elodie, Bergstrand Martin

机构信息

Pharmetheus AB, Uppsala, Sweden.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2025 Feb;14(2):197-216. doi: 10.1002/psp4.13278. Epub 2024 Dec 13.

DOI:10.1002/psp4.13278
PMID:39670923
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11812945/
Abstract

The Markov chain is a stochastic process in which the future value of a variable is conditionally independent of the past, given its present value. Data with Markovian features are characterized by: frequent observations relative to the expected changes in values, many consecutive same-category or similar-value observations at the individual level, and a positive correlation observed between the current and previous values for that variable. In drug development and clinical settings, the data available commonly present Markovian features and are increasingly often modeled using Markov elements or dedicated Markov models. This tutorial presents the main characteristics, evaluations, and applications of various Markov modeling approaches including the discrete-time Markov models (DTMM), continuous-time Markov models (CTMM), hidden Markov models, and item-response theory model with Markov sub-models. The tutorial has a specific emphasis on the use of DTMM and CTMM for modeling ordered-categorical data with Markovian features. Although the main body of this tutorial is written in a software-neutral manner, annotated NONMEM code for all key Markov models is included in the Supplementary Information.

摘要

马尔可夫链是一种随机过程,其中变量的未来值在给定其当前值的情况下,与过去条件独立。具有马尔可夫特征的数据具有以下特点:相对于预期的值变化有频繁的观测值,在个体层面有许多连续的同类别或相似值观测值,并且该变量的当前值与先前值之间存在正相关。在药物开发和临床环境中,可用数据通常呈现马尔可夫特征,并且越来越多地使用马尔可夫元素或专用马尔可夫模型进行建模。本教程介绍了各种马尔可夫建模方法的主要特征、评估和应用,包括离散时间马尔可夫模型(DTMM)、连续时间马尔可夫模型(CTMM)、隐马尔可夫模型以及具有马尔可夫子模型的项目反应理论模型。本教程特别强调使用DTMM和CTMM对具有马尔可夫特征的有序分类数据进行建模。尽管本教程的主体以与软件无关的方式编写,但补充信息中包含了所有关键马尔可夫模型的注释NONMEM代码。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b83/11812945/9d2ebe527a53/PSP4-14-197-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b83/11812945/9803f6973ef4/PSP4-14-197-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b83/11812945/e5146080ed4e/PSP4-14-197-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b83/11812945/801219d730b7/PSP4-14-197-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b83/11812945/8ec15db822c3/PSP4-14-197-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b83/11812945/31bcb3ee4a92/PSP4-14-197-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b83/11812945/9d2ebe527a53/PSP4-14-197-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b83/11812945/9803f6973ef4/PSP4-14-197-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b83/11812945/e5146080ed4e/PSP4-14-197-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b83/11812945/801219d730b7/PSP4-14-197-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b83/11812945/8ec15db822c3/PSP4-14-197-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b83/11812945/31bcb3ee4a92/PSP4-14-197-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b83/11812945/9d2ebe527a53/PSP4-14-197-g006.jpg

相似文献

1
A tutorial on pharmacometric Markov models.药物计量马尔可夫模型教程。
CPT Pharmacometrics Syst Pharmacol. 2025 Feb;14(2):197-216. doi: 10.1002/psp4.13278. Epub 2024 Dec 13.
2
A Minimal Continuous-Time Markov Pharmacometric Model.一个最小连续时间 Markov 药效计量学模型。
AAPS J. 2017 Sep;19(5):1424-1435. doi: 10.1208/s12248-017-0109-1. Epub 2017 Jun 20.
3
Pharmacometrics models with hidden Markovian dynamics.具有隐马尔可夫动态的药物代谢动力学模型。
J Pharmacokinet Pharmacodyn. 2018 Feb;45(1):91-105. doi: 10.1007/s10928-017-9541-1. Epub 2017 Aug 31.
4
Tutorial on how to build non-Markovian dynamic models from molecular dynamics simulations for studying protein conformational changes.从分子动力学模拟构建非马尔可夫动态模型以研究蛋白质构象变化的教程。
J Chem Phys. 2024 Mar 28;160(12). doi: 10.1063/5.0189429.
5
Modeling Movement Primitives with Hidden Markov Models for Robotic and Biomedical Applications.用于机器人和生物医学应用的基于隐马尔可夫模型的运动基元建模
Methods Mol Biol. 2017;1552:199-213. doi: 10.1007/978-1-4939-6753-7_15.
6
Stochastic stability of Markovian jumping uncertain stochastic genetic regulatory networks with interval time-varying delays.具有区间时变时滞的马尔可夫跳变不确定随机基因调控网络的随机稳定性。
Math Biosci. 2010 Aug;226(2):97-108. doi: 10.1016/j.mbs.2010.04.002. Epub 2010 Apr 27.
7
Global exponential stability of neutral high-order stochastic Hopfield neural networks with Markovian jump parameters and mixed time delays.具有马尔可夫跳变参数和混合时滞的中立型高阶随机 Hopfield 神经网络的全局指数稳定性。
ISA Trans. 2013 Nov;52(6):759-67. doi: 10.1016/j.isatra.2013.07.016. Epub 2013 Aug 13.
8
Algorithms for variable length Markov chain modeling.可变长度马尔可夫链建模算法
Bioinformatics. 2004 Mar 22;20(5):788-9. doi: 10.1093/bioinformatics/btg489. Epub 2004 Jan 29.
9
Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM.在 NONMEM 中使用双变量混合隐马尔可夫模型处理潜在离散变量。
J Pharmacokinet Pharmacodyn. 2019 Dec;46(6):591-604. doi: 10.1007/s10928-019-09658-z. Epub 2019 Oct 26.
10
Approaches for modeling within subject variability in pharmacometric count data analysis: dynamic inter-occasion variability and stochastic differential equations.药代动力学计数数据分析中个体内变异性建模方法:动态场合间变异性和随机微分方程。
J Pharmacokinet Pharmacodyn. 2016 Jun;43(3):305-14. doi: 10.1007/s10928-016-9473-1. Epub 2016 May 10.

引用本文的文献

1
Interplay between pharmacokinetics and immunogenicity of therapeutic proteins: stepwise development of a bidirectional joint pharmacokinetics-anti-drug antibodies model.治疗性蛋白质的药代动力学与免疫原性之间的相互作用:双向联合药代动力学-抗药物抗体模型的逐步发展
J Pharmacokinet Pharmacodyn. 2025 May 21;52(3):33. doi: 10.1007/s10928-025-09971-w.
2
Historical Use of Markov Model and Posterior Predictive Checks in Pharmacometrics.马尔可夫模型和后验预测检验在药物计量学中的历史应用。
CPT Pharmacometrics Syst Pharmacol. 2025 May;14(5):817-818. doi: 10.1002/psp4.70031. Epub 2025 Apr 8.

本文引用的文献

1
Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach.采用非线性混合效应方法的双变量混合隐马尔可夫模型对抗体药物动力学的特征描述。
J Pharmacokinet Pharmacodyn. 2024 Feb;51(1):65-75. doi: 10.1007/s10928-023-09890-8. Epub 2023 Nov 9.
2
A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohorts.一种非酒精性脂肪性肝病纤维化发展的马尔可夫模型可预测临床队列中的纤维化进展。
CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):2038-2049. doi: 10.1002/psp4.13052. Epub 2023 Oct 3.
3
A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non-small cell lung cancer.
一种用于学习肿瘤药物剂量反应的多州建模和模拟框架:应用于 bintrafusp alfa 治疗非小细胞肺癌。
CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1738-1750. doi: 10.1002/psp4.12976. Epub 2023 May 11.
4
Dose Delays, Dose Reductions, and Relative Total Dose Intensity in Patients With Advanced Cancer Who Exercised During Neoadjuvant Chemotherapy Treatment.接受新辅助化疗治疗的晚期癌症患者锻炼时的剂量延迟、剂量减少和相对总剂量强度。
Integr Cancer Ther. 2023 Jan-Dec;22:15347354231168368. doi: 10.1177/15347354231168368.
5
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study.多州药代动力学模型以确定二线免疫疗法对IMpower131研究生存结果的影响。
Clin Pharmacol Ther. 2023 Apr;113(4):851-858. doi: 10.1002/cpt.2838. Epub 2023 Jan 29.
6
Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity.基于弥漫性大 B 细胞淋巴瘤研究的利妥昔单抗药代动力学和药代动力学-药效学评价:肿瘤大小对药代动力学的影响及药代动力学相似性评价。
CPT Pharmacometrics Syst Pharmacol. 2023 Feb;12(2):154-167. doi: 10.1002/psp4.12885. Epub 2022 Dec 25.
7
Dose/exposure-response modeling in dose titration trials: Overcoming the titration paradox.剂量/暴露-反应建模在剂量滴定试验中:克服滴定悖论。
CPT Pharmacometrics Syst Pharmacol. 2022 Dec;11(12):1592-1603. doi: 10.1002/psp4.12863. Epub 2022 Sep 20.
8
The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).成人 1 型糖尿病管理。美国糖尿病协会 (ADA) 和欧洲糖尿病研究协会 (EASD) 的共识报告。
Diabetologia. 2021 Dec;64(12):2609-2652. doi: 10.1007/s00125-021-05568-3.
9
Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel.多州模型用于分析 HER2 阴性乳腺癌患者接受多西紫杉醇治疗的总生存期的药代动力学分析。
CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1255-1266. doi: 10.1002/psp4.12693. Epub 2021 Aug 3.
10
Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.良性前列腺增生症继发下尿路症状症状量表的有界整数建模。
AAPS J. 2021 Feb 25;23(2):33. doi: 10.1208/s12248-021-00568-y.